Market capitalization | $41.80m |
Enterprise Value | $83.29m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 4.29 |
EV/Sales (TTM) EV/Sales | 1.47 |
P/S ratio (TTM) P/S ratio | 0.74 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 21.07% |
Revenue (TTM) Revenue | $56.59m |
As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.
2 Analysts have issued a Scilex forecast:
2 Analysts have issued a Scilex forecast:
Dec '24 |
+/-
%
|
||
Revenue | 57 57 |
21%
21%
|
|
Gross Profit | 36 36 |
33%
33%
|
|
EBITDA | -89 -89 |
12%
12%
|
EBIT (Operating Income) EBIT | -93 -93 |
12%
12%
|
Net Profit | -73 -73 |
36%
36%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.
Head office | United States |
CEO | Jaisim Shah |
Employees | 115 |
Founded | 2020 |
Website | www.scilexholding.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.